Erythropoiesis-stimulating agents

Macdougall IC (2005) CERA (Continuous Erythropoietin Receptor Activator) a new erythropoiesis-stimulating agent for the treatment of anemia. Curr Hematol Rep 4 436-440... [Pg.581]

Patients with CKD should be evaluated for anemia when the GFR falls below 60 mL/minute or if the serum creatinine rises above 2 mg/dL (176.8 mmol/L). If the Hgb is less than 11 g/dL (6.8 mmol/L), an anemia work-up should be performed. The work-up for anemia should rule out other potential causes for anemia (see Chapter 63). Abnormalities found during the anemia work-up should be corrected before initiating erythropoiesis-stimulating agents (ESA),... [Pg.383]

The first-line treatment for anemia of CKD involves replacement of erythropoietin with erythropoiesis-stimulating agents (ESAs). Use of ESAs increases the iron demand for RBC production and iron deficiency is common, requiring iron supplementation to correct and maintain adequate iron stores to promote RBC production. Androgens were used extensively... [Pg.385]

Erythropoiesis-stimulating agents Agents developed by recombinant DNA technology that have the same biologic activity as endogenous erythropoietin to stimulate erythropoiesis (red blood cell production) in the bone marrow. [Pg.1565]

TABLE 19.3 Preclinical evidence of carcinogenic risk with erythropoiesis stimulating agents... [Pg.425]

Sinclair AM, Todd MD, Forsythe MD, Knox SJ, Elliott S, Begley CG. Expression and function of erythropoietin receptors in tumors implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 2007 110 477-88. [Pg.473]

Renal anaemia is generally treated with erythropoiesis-stimulating agents (ESAs), of which three are currently in general use the erythropoietins, namely epoetin alfa (Eprex), epoetin beta (NeoRecormon) and darbepoetin alfa (Aranesp). [Pg.375]

Singh FI, Reed J, Noble S,Cangiano JL,Van WyckDB. Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia A randomized, controlled trial. Clin J Am Soc Nephrol 2006 1 475-482. [Pg.890]

B., Carrera, F., Eckardt, K., Macdougall, L, Macleod, A., Ho, W., Wiecek, A., Cameron, S., Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia where are we now and where do we go from here Nephrol Dial Transplant 2004, 19, 288-293. [Pg.1666]

Foley RN. Emerging erythropoiesis-stimulating agents. Nat Rev Nephrol 2010 6(4) 218-23. [Pg.527]

Schrijvers D, De Samblanx H, Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients ESMO Clinical Practice Guidelines for use. Ann Oncol 2010 21(SuppL 5) V244-7. [Pg.528]

Steensma DP. Prospects and perils of retrospective risk assessment of erythropoiesis-stimulating agents. Am J Hematol 2008 83(9) 693. ... [Pg.688]

Gascon P. Safety update on erythropoiesis-stimulating agents trials within and... [Pg.688]

Rx Erythropoietin and Erythropoiesis-Stimulating Agents [SED-15, 1243 SEDA -30, 388 SEDA-31, 538 SEDA-32, 597 SEDA-33, 681]... [Pg.562]

Koulouridis 1, AUayez M, Trikalinos TA, Balk EM, Jaber BL. Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD a metaregression analysis. Am J Kidney Dis 2013 61(l) 44r-56. [Pg.584]

Franz, S.E. (2009) Erythropoiesis-stimulating agents Development, detection, and dangers. Drug Testing and Analysis, 1,245-249. [Pg.258]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...